A new trading day began on Monday, with Verona Pharma Plc ADR (NASDAQ: VRNA) stock price up 4.17% from the previous day of trading, before settling in for the closing price of $26.39. VRNA’s price has ranged from $11.39 to $28.83 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -39.77% over the last five years. Meanwhile, its annual earnings per share averaged -188.89%. With a float of $62.75 million, this company’s outstanding shares have now reached $80.44 million.
The firm has a total of 79 workers. Let’s measure their productivity. In terms of profitability, gross margin is 4.57%, operating margin of -13794.21%, and the pretax margin is -13440.9%.
Verona Pharma Plc ADR (VRNA) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Verona Pharma Plc ADR is 22.61%, while institutional ownership is 62.20%. The most recent insider transaction that took place on Aug 13 ’24, was worth 1,275,681. In this transaction President and CEO of this company sold 398,400 shares at a rate of $3.20, taking the stock ownership to the 15,850,704 shares. Before that another transaction happened on Aug 12 ’24, when Company’s President and CEO sold 1,600 for $3.13, making the entire transaction worth $5,008. This insider now owns 16,249,104 shares in total.
Verona Pharma Plc ADR (VRNA) Recent Fiscal highlights
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.18 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -188.89% per share during the next fiscal year.
Verona Pharma Plc ADR (NASDAQ: VRNA) Trading Performance Indicators
Here are Verona Pharma Plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.56, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.20 in one year’s time.
Technical Analysis of Verona Pharma Plc ADR (VRNA)
Analysing the last 5-days average volume posted by the [Verona Pharma Plc ADR, VRNA], we can find that recorded value of 1.16 million was better than the volume posted last year of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 61.44%. Additionally, its Average True Range was 1.69.
During the past 100 days, Verona Pharma Plc ADR’s (VRNA) raw stochastic average was set at 92.32%, which indicates a significant increase from 74.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.29% in the past 14 days, which was lower than the 65.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $23.02, while its 200-day Moving Average is $17.67. Now, the first resistance to watch is $28.24. This is followed by the second major resistance level at $29.00. The third major resistance level sits at $30.22. If the price goes on to break the first support level at $26.26, it is likely to go to the next support level at $25.04. Now, if the price goes above the second support level, the third support stands at $24.28.
Verona Pharma Plc ADR (NASDAQ: VRNA) Key Stats
With a market capitalization of 2.23 billion, the company has a total of 79,940K Shares Outstanding. Currently, annual sales are 0 K while annual income is -54,370 K. The company’s previous quarter sales were 0 K while its latest quarter income was -70,840 K.
